Farther Finance Advisors LLC Reduces Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Farther Finance Advisors LLC lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 39.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 137 shares of the medical research company’s stock after selling 89 shares during the quarter. Farther Finance Advisors LLC’s holdings in Charles River Laboratories International were worth $27,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Cambiar Investors LLC lifted its stake in Charles River Laboratories International by 1.1% during the 3rd quarter. Cambiar Investors LLC now owns 45,930 shares of the medical research company’s stock worth $9,047,000 after acquiring an additional 494 shares in the last quarter. Stephens Inc. AR increased its position in shares of Charles River Laboratories International by 126.9% during the third quarter. Stephens Inc. AR now owns 5,463 shares of the medical research company’s stock worth $1,076,000 after acquiring an additional 3,055 shares during the period. Iridian Asset Management LLC CT raised its stake in shares of Charles River Laboratories International by 19.2% in the third quarter. Iridian Asset Management LLC CT now owns 55,043 shares of the medical research company’s stock valued at $10,842,000 after acquiring an additional 8,876 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in Charles River Laboratories International by 2.6% in the third quarter. State of Alaska Department of Revenue now owns 15,899 shares of the medical research company’s stock valued at $3,131,000 after purchasing an additional 405 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at about $246,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 4.7 %

CRL opened at $187.74 on Friday. The business has a 50 day simple moving average of $195.26 and a 200-day simple moving average of $207.52. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The stock has a market capitalization of $9.60 billion, a P/E ratio of 23.50, a P/E/G ratio of 5.33 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.72 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a stock buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CRL shares. TD Cowen boosted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. UBS Group lifted their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. CLSA raised Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 target price for the company in a research report on Thursday, November 7th. Finally, Bank of America cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $217.54.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).